Literature DB >> 26429894

Adverse pregnancy outcomes following syphilis treatment in pregnancy in the UK.

Harriet E Wallace1, Catherine E Isitt2, Harriet M Broomhall2, Alison E Perry3, Janet D Wilson4.   

Abstract

Syphilis infection in pregnancy is known to cause a number of severe adverse pregnancy outcomes, including second-trimester miscarriage, stillbirth, very pre-term delivery and neonatal death, in addition to congenital syphilis. A retrospective review of women with positive syphilis serology and a pregnancy outcome between 2005 and 2012 in Leeds, UK, was performed. In all, 57 cases of positive syphilis serology in pregnancy were identified: 24 with untreated syphilis treated in the current pregnancy (Group 1); seven with reported but unconfirmed prior treatment who were retreated (Group 2); and 26 adequately treated prior to pregnancy (Group 3). The rate of severe adverse pregnancy outcomes in Group 1 at 21% was significantly higher than the 0% outcome of Group 3 (p = 0.02). The severe adverse pregnancy outcomes were two second-trimester miscarriages, two pre-term births at 25 and 28 weeks and one stillbirth at 32 weeks. There were no cases of term congenital syphilis or term neonatal death, but we observed high rates of other adverse pregnancy outcomes despite treatment during pregnancy. Rapid referral for treatment is needed before 18 weeks in order to minimise adverse pregnancy outcomes.
© The Author(s) 2016.

Entities:  

Keywords:  Syphilis; Treponema pallidum; adverse pregnancy outcomes; congenital syphilis; pregnancy; women

Mesh:

Substances:

Year:  2015        PMID: 26429894     DOI: 10.1177/0956462415609862

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  Treatment evaluation to improve preventing mother to child transmission among women with syphilis.

Authors:  Tian Gong; Yan Shao; Juning Liu; Qianlan Wu; Rong Xu; Li Sun; Xiaoju Peng
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.